Routine Laboratory Monitoring in HIV Patients
All HIV-positive patients require a comprehensive initial laboratory evaluation followed by regular monitoring of CD4 count, viral load, complete blood count, chemistry panel, and fasting lipids, with additional tests based on individual risk factors and treatment regimens. 1
Initial Laboratory Evaluation (At Entry to Care)
Core Baseline Tests
- CD4 cell count and HIV viral load - Essential for staging disease and determining treatment urgency 1
- Complete blood count (CBC) with differential - Screens for anemia, leukopenia, and thrombocytopenia, which are common in HIV; also needed to calculate absolute CD4 count 1
- Comprehensive metabolic panel - Assesses baseline renal and hepatic function before initiating potentially nephrotoxic or hepatotoxic antiretroviral therapy 1
- Fasting lipid profile - Establishes baseline before ART, as many antiretrovirals, HIV itself, and host factors increase cholesterol and triglycerides 1
- Fasting glucose and/or HbA1c - Screens for glucose intolerance and diabetes, which have increased prevalence in HIV-infected populations 1
- Urinalysis for proteinuria - Particularly important in high-risk patients (Black race, CD4 <200 cells/µL, viral load >4,000 copies/mL, diabetes, hypertension, or HCV coinfection) 1
Infectious Disease Screening
- Tuberculosis testing (TST or IGRA) - Required for all patients without prior positive test or TB history; induration >5mm is positive in HIV patients 1
- Toxoplasma IgG serology - Identifies the 10-30% of US patients at risk for toxoplasmosis reactivation 1
- Syphilis screening - Non-specific test followed by confirmatory testing if positive 1
- Hepatitis B and C serology - Essential for coinfection management 1
Pharmacogenetic and Pre-Treatment Testing
- HLA-B*5701 testing - Must be performed before initiating abacavir to prevent hypersensitivity reactions 1
- G6PD deficiency screening - Required before starting dapsone, primaquine, or sulfonamides in patients of African, Mediterranean, Indian, or Southeast Asian descent 1
- Baseline resistance testing - Genotypic resistance testing should guide initial ART selection 1
Ongoing Monitoring Schedule
Routine Follow-Up Tests
CD4 count and viral load monitoring:
- Initially more frequent until viral suppression achieved
- After stable suppression on ART, frequency can be reduced
- CD4 monitoring helps assess immune reconstitution and need for opportunistic infection prophylaxis
Chemistry panel and CBC:
- Regular monitoring to detect drug toxicities (myelosuppression, nephrotoxicity, hepatotoxicity)
- Frequency depends on specific ART regimen and baseline abnormalities 1
Fasting lipids:
- Periodic monitoring given increased cardiovascular risk with both HIV and certain antiretrovirals 1
Urinalysis:
- Annual screening for proteinuria, especially in high-risk patients
- Grade ≥1+ proteinuria or reduced kidney function warrants nephrology referral and quantification 1
Treatment-Specific Monitoring
Creatinine monitoring considerations:
- Be aware that cobicistat, dolutegravir, and trimethoprim elevate serum creatinine by affecting tubular secretion without true renal dysfunction 1
- This is a laboratory artifact, not actual kidney injury
Resistance testing:
- Genotypic resistance testing at virologic failure to guide regimen modification 1
- INSTI resistance testing specifically for integrase inhibitor failures 1
Tropism testing:
- Only if CCR5 antagonist (maraviroc) is being considered; not routine 1
Special Circumstances
Repeat TB Testing
- Indicated when CD4 count increases to >200 cells/µL on ART in patients with initial negative TST/IGRA who may now have sufficient immune function to mount a positive reaction 1
- Annual testing for those with ongoing TB exposure risk 1
Pregnancy
- All pregnant women require first-trimester HIV screening, with third-trimester repeat for high-risk patients 2
Common Pitfalls to Avoid
- Don't dismiss elevated creatinine on certain ART regimens - Distinguish between true nephrotoxicity and benign creatinine elevation from tubular secretion inhibition 1
- Don't skip HLA-B*5701 testing - Abacavir hypersensitivity can be life-threatening and is preventable with pre-treatment screening 1
- Don't use CCR5 antagonists without tropism testing - Risk of virologic failure if X4 or dual/mixed tropic virus is present 1
- Don't overlook proteinuria screening in high-risk patients - Early detection and nephrology referral can prevent progression of kidney disease 1
The evidence strongly supports this comprehensive approach, with the 2014 IDSA/HIVMA guidelines 1 providing the most authoritative framework for laboratory monitoring in HIV care.